Stock Events

Stock Events

Cytodyn 

$0.2327
42
-$0.00-1.69% 13:32 Today

Statistics

Day High
0.2426
Day Low
0.2211
52W High
0.4
52W Low
0.18
Volume
428,836
Avg. Volume
1,695,949
Mkt Cap
317.87M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
0Revenue
3.75MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CYDY. It's not an investment recommendation.
Schwab US Dividend Equity
7
SCHD
Apple
6
AAPL
Amazon
4
AMZN
Vanguard S&P 500
4
VOO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that competes with CytoDyn in the HIV and other antiviral drug markets, making it a direct competitor.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline, through its HIV drugs division ViiV Healthcare, competes in the HIV treatment space, directly challenging CytoDyn's efforts.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. offers a range of antiviral and immunotherapy products that compete with CytoDyn's treatments for various diseases, including HIV.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for HIV/AIDS, making it a competitor in the same market as CytoDyn.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is involved in the development of drugs for infectious diseases, including HIV, which puts it in competition with CytoDyn.
Arbutus Biopharma
ABUS
Mkt Cap1B
Arbutus Biopharma Corporation works on antiviral therapies, including for HIV, potentially competing with CytoDyn's product pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is engaged in the creation of treatments for a range of diseases, including viral infections, which could make it a competitor to CytoDyn.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a portfolio of HIV treatments that compete with CytoDyn's offerings in the HIV therapy market.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation works on drugs for various diseases, including those with antiviral applications, potentially putting it in competition with CytoDyn.

About

CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Show more...
CEO
Jacob Lalezari
Employees
13
Country
United States
ISIN
US23283M1018

Listings

STU
DE
296.STU
MU
DE
296.MU
OTC Link
US
CYDY

0 Comments

Share your thoughts

FAQ

What is Cytodyn stock price today?▼
The current price of CYDY is $0.23 USD — it has decreased by -1.69% in the past 24 hours. Watch Cytodyn stock price performance more closely on the chart.
What is Cytodyn stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Cytodyn stocks are traded under the ticker CYDY.
Is Cytodyn stock price growing?▼
CYDY stock has fallen by -0.13% compared to the previous week, the month change is a +24.58% rise, over the last year Cytodyn has showed a -19.76% decrease.
What is Cytodyn market cap?▼
Today Cytodyn has the market capitalization of 317.87M
When is the next Cytodyn earnings date?▼
Cytodyn is going to release the next earnings report on October 28, 2026.
What is Cytodyn revenue for the last year?▼
Cytodyn revenue for the last year amounts to 0 USD.
What is Cytodyn net income for the last year?▼
CYDY net income for the last year is 3.75M USD.
How many employees does Cytodyn have?▼
As of September 01, 2026, the company has 13 employees.
In which sector is Cytodyn located?▼
Cytodyn operates in the Health & Wellness sector.
When did Cytodyn complete a stock split?▼
Cytodyn has not had any recent stock splits.
Where is Cytodyn headquartered?▼
Cytodyn is headquartered in Vancouver, United States.